A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

NCT03524612 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune Thrombocytopenic Purpura (ITP)

Interventions

DRUG: eltrombopag

Sponsor

Novartis Pharmaceuticals